Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

NCT05287399 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: ASC61 200 mg 1
DRUG: ASC61 200 mg 2
DRUG: ASC61 300 mg
DRUG: ASC61 400 mg
DRUG: ASC61 600 mg
DRUG: ASC61 800 mg

Sponsor

Ascletis Pharmaceuticals Co., Ltd.